A Confirmatory Trial of ETC-1002 in Patients With Hyper-LDL Cholesterolemia

Otsuka

Status and phase: Completed; Phase 3

Conditions: Hyper-low-density Lipoprotein (LDL) Cholesterolemia

Treatments: Drug: 180mg of ETC-1002(bempedoic acid); Drug: Placebo

Study type: Interventional

Funder types: Industry

Identifiers

NCT05683340

346-102-00002

Details and patient eligibility

About

The purpose of this study is to confirm the superiority of ETC-1002 after 12 weeks of administration at 180 mg/day to placebo in patients with hyper-LDL cholesterolemia who have inadequate control of low-density lipoprotein cholesterol (LDL C).

Enrollment: 96 patients

Sex: All

Ages: 18 to 85 years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Patients with inadequate response to statins or statin intolerance as defined below [Inadequate response to statins] Patients with hyper-LDL cholesterolemia who have been taking statins[and other lipid-modifying therapies(LMTs) if needed] and cannot achieve the lipid management goals of LDL-C [Statin intolerance] Patients with hyper-LDL cholesterolemia for whom safety problems have occurred while taking at least one type of statin, and who experienced resolution of the problems after discontinuation or dose reduction, and who cannot achieve the lipid management goals of LDL-C. Patients must be on the lowest or under the dosage of the approved dose of statin and/or on stable LMT(s).
• Patients with fasting TG levels of <400 mg/dL at screening
• Other protocol specific inclusion criteria may apply

Exclusion criteria

• Females who are pregnant or breast-feeding or who have a positive pregnancy test (urine) result at screening or baseline visits

• Patients with homozygous familial hypercholesterolemia (HoFH)

• Patients who currently have or who have had within the past 3 months prior to screening any cardiovascular diseases, or those who have developed any cardiovascular diseases during the screening or before baseline visit

• Uncontrolled hypertension, defined as sitting systolic blood pressure after resting 5 minutes of ≥160 mmHg or diastolic blood pressure of ≥100 mmHg at screening

• Patients with uncontrolled and serious hematologic or coagulation disorders or with hemoglobin of <10.0 g/dL at screening

• Patients with uncontrolled diabetes with HbA1c of ≥9% at screening

• Patients with uncontrolled hypothyroidism with thyroid-stimulating hormone (TSH) of >1.5 × ULN at screening

• Patients with liver disease or dysfunction, including:

  • Positive serology for hepatitis B surface antigen (HBsAg) or a positive hepatitis C virus (HCV) antibody test at screening
  • Alanine aminotransferase (ALT) or aspartate aminotransferase (AST) of ≥3 × ULN or total bilirubin of ≥2 × ULN at screening

• Patients with creatine kinase (CK) of >3 × ULN at screening

• Patients with a history or current renal dysfunction, nephritic syndrome, or nephritis, and with estimated glomerular filtration rate (eGFR) of ≤30 mL/min/1.73 m2 at screening

• Other protocol specific exclusion criteria may apply

Trial design

Primary purpose: Treatment

Allocation: Randomized

Interventional model: Parallel Assignment

Masking: Quadruple Blind

---

96 participants in 2 patient groups, including a placebo group

ETC-1002 180mg

Experimental group

Treatment:

Drug: 180mg of ETC-1002(bempedoic acid)

Placebo

Placebo Comparator group

Treatment:

Drug: Placebo